Based on the linked source; automatically prepared and checked against the original report.
Study focus
The analysis examined whether siponimod delayed sustained Expanded Disability Status Scale scores of at least 7.0, defined in the study as requiring a wheelchair. Researchers assessed participants with secondary progressive multiple sclerosis during the core phase 3 EXPAND study, comparing siponimod with placebo. The report is an abstract summary rather than a review of the full paper, and its findings are not treatment recommendations.
Overall findings
Across the overall EXPAND population, siponimod was associated with a 40% lower risk of reaching sustained EDSS 7.0 than placebo. The reported hazard ratio was 0.60, with a 95% confidence interval of 0.41 to 0.88 and p=0.009. The analysis used a While on Treatment population, censoring participants who entered open-label treatment.
Disease activity and interpretation
The reported risk reduction was 51% among participants with active SPMS, based on pre-study or baseline criteria, with a hazard ratio of 0.49. Among those with non-active SPMS, the reduction was 22%, with a hazard ratio of 0.78 and p=0.437. Separate analyses also considered participants whose baseline EDSS was 6.5. The authors concluded that the apparent effect was greater in active disease.
